News 2020

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

Pittsburgh, October 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors. Dr. Monia is a founding member and the current CEO of Ionis Pharmaceuticals, a pioneer in …

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors Read More »

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease

Pittsburgh, October 19, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal …

Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease Read More »

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812

Pittsburgh, August 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease. The study is …

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812 Read More »

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer’s Clinical Trials Consortium

New York, June 8, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected …

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer’s Clinical Trials Consortium Read More »

Cognition Therapeutics Announces Change in Leadership

New York, March 27, 2020 — Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Kenneth I. Moch has stepped down as president and chief executive officer to assume an advisory role. Lisa Ricciardi has transitioned from …

Cognition Therapeutics Announces Change in Leadership Read More »

Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer’s Disease

NEW YORK, March 17, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of an article titled, The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s Disease, which reviews the …

Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer’s Disease Read More »

Scroll to Top